Wall Street analysts will be watching closely when MEDNAX, Inc. (NYSE:MD) reports its quarterly earnings next, which is scheduled for Thu 14 Feb (In 32 Days). Looking at the latest analyst forecasts, the current earnings-per-share (EPS) consensus estimate is sitting at $1.09 per share. In the preceding quarter, the company reportedly generated EPS of $0.94 per share of its common stock. Looking at profitability indicators, this organization has an operating margin of 12.90%, a profit margin of 9.50% and a gross margin of .
Speaking of Wall Street analysts, a number of market experts at top investment banks have recently posted their updated ratings on shares of MEDNAX, Inc. (NYSE:MD). Most recently, on January 3rd, 2019, Deutsche Bank Initiated a Hold rating. Before that, on November 16th, 2018, UBS Initiated to Sell. Leerink Partners Upgrade a Outperform rating on September 24th, 2018, BofA/Merrill Upgrade an Neutral rating on September 18th, 2018, and Credit Suisse Upgrade a Outperform rating on August 3rd, 2018.
At its current price point, combined with the fact that this company has 88.75M shares outstanding, the current market capitalization sits at 3.09B. In the last trading day, 559,824 shares of MEDNAX, Inc. were traded, which compares to its usual volume of about 1.11M shares per day of trading.
If we compare this company’s current price to its recent pricing activity, we can see that the price has changed by $1.82 in the past five trading days, resulting in a percentage change of +5.52% and a moving average of 34.45. In the past 20 days, its price changed by -$3.52 (which is -9.19%) and the stock’s moving average was 33.95. Looking back a full 50 days, shares of MD changed by -$6.24 (which is -15.21%) and demonstrated a moving average of 37.40.
Staying in the same analytical area, this company’s stock has demonstrated a 9-day Stochastic %K score of 84.29%, a 14-day Stochastic %K score of 81.21% and a 20-day Stochastic %K score of 40.76%. Using a similar metric, MEDNAX, Inc. (MD) shares showed a Stochastic %D of 86.44% over the past 9 days, a Stochastic %D score of 70.55% over the last 14 days, and a 20-day Stochastic %D of 36.30%. Meanwhile, this stock’s MACD Oscillator was 1.02 over the past 9 days, 1.39 over the past two weeks, and 0.74 in the last 20 days.
As recent trading data suggests, this company’s shares have been hovering close to the $34.78 level. Over the past 12 months, this stock has experienced a high price of $63.04 and a low of $31.68. Top market experts pay heightened attention to a stock as it is getting closer to a notable historic high price or low price.
T Rowe Price Associates Inc sold more shares of this company during the last fiscal quarter, as we can observe in the latest corresponding filing from MEDNAX, Inc. (NYSE:MD) with the Securities and Exchange Commission (SEC). This specific major shareholder, at the end of the quarter, held 8,422,948 shares of the company’s stock following the subtraction of -137,732 to this investor’s holdings during the three-month period. This share count represents that T Rowe Price Associates Inc now held 9.42% stake in MEDNAX, Inc. (MD)’s shares.
Just in the most recent trading day, MEDNAX, Inc. (NYSE:MD) experienced a high price of $34.93 and low point of $34.085. At the end of the last trading session, this stock was at 34.78 per share, following a loss of -$0.18, or 0.75% during the full day.